Navigation Links
Symmetry Medical Reports Third Quarter 2008 Financial Results
Date:11/12/2008

ompany's domestic forging operations as a result of a large press break down. The impact of these unfavorable items more than offset the lower loss experienced at our Sheffield operations of $0.8 million.

Gross margin percentage for the third quarter 2008 was 22.9% compared to gross margin percentage of 14.9% for the third quarter 2007.

Selling, general and administrative expenses were $15.2 million for the third quarter 2008, compared to $9.0 million in the third quarter 2007. The year-over-year increase was driven by $2.3 million from the addition of expenses from the recent acquisitions, $0.9 million from the remaining professional fees and expenses related to the review of accounting irregularities at the Sheffield, UK operating unit and $0.7 million from an increase in restricted stock expense. The remaining increase is a result of increased sales commission expense to support the higher sales levels and general inflation.

Operating income for the third quarter of 2008 was $10.5 million, up 359.9% from $2.3 million for the third quarter 2007. Operating margin for the third quarter 2008 was 9.4%, an increase from 3.0% for the third quarter 2007. In addition to several items in gross profit and SG&A mentioned above, operating income was negatively impacted by continuing operating losses at the Sheffield UK unit.

The third quarter 2008 net income included the unfavorable gross margin items worth $1.6 million or ($0.03) per share, a net unfavorable foreign exchange impact of $2.1 million or ($0.04) per share primarily at our Sheffield, UK operating unit, the impact of recording a full tax valuation allowance on current year losses at the Sheffield, UK operating unit of $1.1 million or ($0.03) per share, and the remaining Sheffield investigation expenses of $0.9 million or ($0.02) per share. Given these items, the net loss at Sheffield was $4.7 million compared to a net loss of $3.2 million in the second quarter of 2008. The Company i
'/>"/>

SOURCE Symmetry Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
2. Symmetry Medical Launches New Global Web site
3. Symmetry Medical Appoints John Hynes Chief Operating Officer, Europe
4. Symmetry Medical Provides Update of Previously Disclosed Accounting Review at Sheffield, UK Operating Unit
5. Symmetry Medical Completes Acquisition of DePuy Orthopaedic Instrument Facility
6. Symmetry Medical to Provide Fourth Quarter 2007 General Business Update on February 14, 2008
7. Facial asymmetry persists despite surgery to correct congenital deformity
8. Symmetry Medical to Expand Malaysian Operations
9. Symmetry Medical Delays 10-K Filing to Complete Review
10. Symmetry Medical Reports Full Year 2007 Financial Results
11. Symmetry Medical to Report First Quarter 2008 Financial Results on June 24, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy 2Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy 3NetMotion Wireless Boosts Mobile Productivity for Bell Ambulance 53877 1NetMotion Wireless Boosts Mobile Productivity for Bell Ambulance 53877 2NetMotion Wireless Boosts Mobile Productivity for Bell Ambulance 53877 3Cooperation Between Faith Based Organizations and UNFPA Critical to Maternal Health Say Groups 53875 1Cooperation Between Faith Based Organizations and UNFPA Critical to Maternal Health Say Groups 53875 2President Clinton and Mylan Chairman and CEO Robert J Coury Announce New Agreement to Lower Price of Treatment for Patients with Drug Resistant HIV i 53873 1President Clinton and Mylan Chairman and CEO Robert J Coury Announce New Agreement to Lower Price of Treatment for Patients with Drug Resistant HIV i 53873 2President Clinton and Mylan Chairman and CEO Robert J Coury Announce New Agreement to Lower Price of Treatment for Patients with Drug Resistant HIV i 53873 3President Clinton and Mylan Chairman and CEO Robert J Coury Announce New Agreement to Lower Price of Treatment for Patients with Drug Resistant HIV i 53873 4